OverviewSuggest Edit

Sonnet BioTherapeutics (formerly known as Chanticleer Holdings) is an oncology-focused biotechnology company. It develops a platform for biologic medicines of single- or bi-specific actions and provides FHAB (fully human albumin binding) drug accumulation improvement technology. The FHAB technology serves immunotherapy, drug conjugation, vaccine developers, and chimeric antigen receptor T cells (CAR T-cell) therapy.

TypePublic
Founded2011
HQPrinceton, NJ, US
Websitesonnetbio.com

Latest Updates

Employees (est.) (Sept 2021)9
Revenue (FY, 2021)$483.6 K(-98%)
Share Price (Jan 2022)$0.3(-2%)
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Sonnet BioTherapeutics

Pankaj Mohan

Pankaj Mohan

Founder, CEO & Chairman
Jay Cross

Jay Cross

Chief Financial Officer
John K. Cini

John K. Cini

Chief Scientific Officer & Co-Founder
Susan Dexter

Susan Dexter

Chief Technical Officer
Richard Kenney

Richard Kenney

Chief Medical Officer
Show more

Sonnet BioTherapeutics Office Locations

Sonnet BioTherapeutics has an office in Princeton
Princeton, NJ, US (HQ)
100 Overlook Center
Show all (1)

Sonnet BioTherapeutics Financials and Metrics

Sonnet BioTherapeutics Revenue

Sonnet BioTherapeutics's revenue was reported to be $483.63 k in FY, 2021
USD

Revenue (FY, 2021)

483.6k

Net income (FY, 2021)

(25.0m)

EBIT (FY, 2021)

(25.1m)

Market capitalization (24-Jan-2022)

19.5m

Closing stock price (24-Jan-2022)

0.3

Cash (30-Sept-2021)

27.6m

EV

(8.0m)
Sonnet BioTherapeutics's current market capitalization is $19.5 m.
Annual
USDFY, 2019FY, 2020FY, 2021

Revenue

30.1m483.6k

Revenue growth, %

(26%)

Cost of goods sold

9.5m

Gross profit

20.6m
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021

Revenue

10.2m10.7m9.7m5.7m

Cost of goods sold

3.3m3.5m3.2m1.8m

Gross profit

6.9m7.2m6.5m3.9m

Gross profit Margin, %

68%67%67%68%
Annual
USDFY, 2019FY, 2020FY, 2021

Cash

500.7k7.3m27.6m

Accounts Receivable

131.9k

Inventories

287.1k

Current Assets

1.2m7.6m28.8m
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021

Cash

561.8k579.0k637.3k548.9k3.1m2.3m6.7m6.0m

Accounts Receivable

523.4k518.9k224.0k63.1k

Inventories

424.6k421.0k354.3k271.5k

Current Assets

1.7m1.8m3.5m1.8m3.5m2.7m7.4m7.0m
Annual
USDFY, 2019FY, 2020FY, 2021

Net Income

(18.5m)(24.3m)(25.0m)

Depreciation and Amortization

1.8m8.3k12.5k

Inventories

(68.2k)

Accounts Payable

2.1m168.8k1.7m
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021

Net Income

(2.0m)(5.3m)(9.6m)(1.8m)(16.7m)(5.9m)(11.9m)(18.0m)

Depreciation and Amortization

542.4k1.1m1.6m415.8k5.2k3.1k6.2k9.2k

Inventories

44.3k41.2k17.4k12.8k

Accounts Payable

739.8k2.4m1.0m(196.0k)533.0k201.9k(144.0k)93.2k
USDQ1, 2019

Debt/Equity

4.4 x

Debt/Assets

0.6 x

Financial Leverage

6.9 x
Show all financial metrics

Sonnet BioTherapeutics Operating Metrics

Sonnet BioTherapeutics's Patients was reported to be 214 in FY, 2021.
FY, 2019FY, 2020FY, 2021

Franchise Agreements

11

Franchised Restaurants

46

Locations (US)

38

Patients

214214
Show all operating metrics

Sonnet BioTherapeutics Acquisitions / Subsidiaries

Company NameDateDeal Size
Chanticleer Holdings , Inc.April 01, 2020
Sonnet BioTherapeutics CH SA
Sonnet BioTherapeutics, Inc.

Sonnet BioTherapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

95/100

SecurityScorecard logo

Sonnet BioTherapeutics Online and Social Media Presence

Embed Graph

Sonnet BioTherapeutics News and Updates

Thinking about buying stock in Sonnet BioTherapeutics, Vinco Ventures, Regional Health Properties, Zomedica, or Support.com?

NEW YORK, Aug. 31, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SONN, BBIG, RHE, ZOM, and SPRT. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Thinking about buying stock in Sonnet BioTherapeutics, Progenity, Hexo Corp, SunLink Health Systems, or Endo International?

NEW YORK, Aug. 20, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SONN, PROG, HEXO, SSY, and ENDP. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Thinking about buying stock in Sonnet BioTherapeutics, Biocept, ReShape Lifesciences, Tencent Music Entertainment, or Cleveland-Cliffs?

NEW YORK, Aug. 19, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SONN, BIOC, RSLS, TME, and CLF. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Thinking about buying stock in Sonnet BioTherapeutics, CHF Solutions, Harmonic Inc, Tiziana Life Sciences, or Seanergy Maritime Holdings?

NEW YORK, Aug. 4, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SONN, CHFS, HLIT, TLSA, and SHIP. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Sonnet BioTherapeutics Blogs

Sonnet BioTherapeutics Provides Fiscal Year 2021 Business and Financial Update

PRINCETON, NJ / ACCESSWIRE / December 17, 2021 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs, announced today its financial results for the fiscal year ended September 30th, 2021 and provid…

Sonnet Announces Successful Completion of the Discovery Phase for Its Next Preclinical Pipeline Candidate (SON-1410)

SON-1410 (IL18-FHAB-IL12), a bispecific combination of Interleukins 18 and 12, was selected based on data generated in a mouse melanoma study comparing three bispecific constructs Selection of the asset was performed with input from Sonnet's Scientific Advisory Board An IND submission for SON-1410 …

Sonnet BioTherapeutics Announces Pricing of $30 Million Underwritten Public Offering

PRINCETON, NJ / ACCESSWIRE / August 19, 2021 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs, today announced the pricing of an underwritten public offering of 35,294,117 shares of common sto…

Sonnet BioTherapeutics Provides Fiscal Year 2021 Third Quarter Business and Earnings Update

Sonnet BioTherapeutics Provides Fiscal Year 2021 Third Quarter Business and Earnings Update Expanded F H AB Intellectual Property Portfolio Completed $15.9 million At-The-Market Financing SON-1010 and SON-080 on track for IND submissions by calendar year end PRINCETON, NJ / ACCESSWIRE / August …

Sonnet BioTherapeutics Announces Change in Date of Annual Meeting

Annual Meeting to be Held Thursday July 15, 2021. PRINCETON, NJ / ACCESSWIRE / June 14, 2021 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a biopharmaceutical company developing innovative targeted biologic drugs, announced today that it has changed the date of its upcoming annual meeting o…

Sonnet BioTherapeutics Announces Issuance of U.S. Patent for Platform Technology

U.S. Patent and Trademark Office issued US Patent No. 11,028,166 for the Company's Fully Human Albumin Binding Domain Fusion Proteins PRINCETON, NJ / ACCESSWIRE / June 8, 2021 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a biopharmaceutical company developing innovative targeted biologic d…
Show more

Sonnet BioTherapeutics Frequently Asked Questions

  • When was Sonnet BioTherapeutics founded?

    Sonnet BioTherapeutics was founded in 2011.

  • Who are Sonnet BioTherapeutics key executives?

    Sonnet BioTherapeutics's key executives are Pankaj Mohan, Jay Cross and John K. Cini.

  • How many employees does Sonnet BioTherapeutics have?

    Sonnet BioTherapeutics has 9 employees.

  • What is Sonnet BioTherapeutics revenue?

    Latest Sonnet BioTherapeutics annual revenue is $483.6 k.

  • What is Sonnet BioTherapeutics revenue per employee?

    Latest Sonnet BioTherapeutics revenue per employee is $53.7 k.

  • Who are Sonnet BioTherapeutics competitors?

    Competitors of Sonnet BioTherapeutics include Cugene, Forbius and Immuneoncia Therapeutics.

  • Where is Sonnet BioTherapeutics headquarters?

    Sonnet BioTherapeutics headquarters is located at 100 Overlook Center, Princeton.

  • Where are Sonnet BioTherapeutics offices?

    Sonnet BioTherapeutics has an office in Princeton.

  • How many offices does Sonnet BioTherapeutics have?

    Sonnet BioTherapeutics has 1 office.